Severe ocular Mpox in person living with advanced HIV treated with extended course of tecovirimat.
Mpox
corneal ulcer
immune reconstitution
keratitis
monkeypox
ocular complications
ophthalmology
viral infection
Journal
HIV medicine
ISSN: 1468-1293
Titre abrégé: HIV Med
Pays: England
ID NLM: 100897392
Informations de publication
Date de publication:
09 May 2024
09 May 2024
Historique:
received:
02
03
2024
accepted:
24
04
2024
medline:
10
5
2024
pubmed:
10
5
2024
entrez:
10
5
2024
Statut:
aheadofprint
Résumé
People living with HIV are disproportionately represented among people with severe mpox. Mild and self-limiting conjunctival involvement has been well-documented, and severe ocular complications, including keratitis, corneal scarring, and the associated loss of vision, are increasingly recognized. Tecovirimat is the first-line antiviral therapy for severe mpox, but data around the efficacy of systemic antiviral agents for mpox are limited, particularly in cases of ocular mpox. Here, we describe a case of sight-threatening necrotic blepharokeratoconjunctivitis in a person with advanced HIV, requiring an extended course of tecovirimat due to persistent mpox viral shedding for nearly 5 months.
Sections du résumé
BACKGROUND
BACKGROUND
People living with HIV are disproportionately represented among people with severe mpox. Mild and self-limiting conjunctival involvement has been well-documented, and severe ocular complications, including keratitis, corneal scarring, and the associated loss of vision, are increasingly recognized. Tecovirimat is the first-line antiviral therapy for severe mpox, but data around the efficacy of systemic antiviral agents for mpox are limited, particularly in cases of ocular mpox.
CASE REPORT
METHODS
Here, we describe a case of sight-threatening necrotic blepharokeratoconjunctivitis in a person with advanced HIV, requiring an extended course of tecovirimat due to persistent mpox viral shedding for nearly 5 months.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 The Authors. HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association.
Références
Mitjà O, Alemany A, Marks M, et al. Mpox in people with advanced HIV infection: a global case series. Lancet. 2023;401:939‐949.
Uner OE, Hubbard DCI, Torres‐Quinones C, et al. Human MPox (monkeypox) virus membranous keratoconjunctivitis with transient corneal hypoesthesia and late Symblepharon formation: a novel case and clinical implications. Cornea. 2023;42(6):751‐754.
Bhamray‐Sanchez D, Subramanian S, Dever LL, Chew D. Ocular MPox: a report of two cases. IDCases. 2023;31:e01706.
Vasquez‐Perez A, Magan T, Volpe G, Osborne SF, McFaul K, Vahdani K. Necrotizing Blepharoconjunctivitis and keratitis in human monkeypox. JAMA Ophthalmol. 2023;141(3):285‐288.
Milligan AL, Koay S‐y, Dunning J. Monkeypox as an emerging infectious disease: the ophthalmic implications. Br J Ophthalmol. 2022;106(12):1629‐1634.
Benatti SV, Venturelli S, Comi N, Borghi F, Paolucci S, Baldanti F. Ophthalmic manifestation of monkeypox infection. Lancet Infect Dis. 2022;22(9):1397.
Malone SM, Mitra AK, Onumah NA, et al. Safety and efficacy of post‐eradication smallpox vaccine as an Mpox vaccine: a systematic review with meta‐analysis. Int J Environ Res Public Health. 2023;20(4):2963.
Grosenbach DW, Honeychurch K, Rose EA, et al. Oral tecovirimat for the treatment of smallpox. N Engl J Med. 2018;379(1):44‐53.
ISRCTN17461766. Antiviral treatment with tecovirimat for patients managed at home with monkeypox (PLATINUM) [Placebo‐controlled randomised trial of tecovirimat in non‐hospitalised monkeypox patients (PLATINUM)]. doi:10.1186/ISRCTN17461766
NCT05534984. Study of tecovirimat for human monkeypox virus (STOMP) [A randomized, placebo‐controlled, double‐blinded trial of the safety and efficacy of tecovirimat for the treatment of human monkeypox virus disease]. http://clinicaltrials.gov/ct2/show/NCT05534984
Pettit NN, Imam S, Sherer R, Hazra A. Treatment options for severe or refractory mpox virus infection in patients with advanced HIV. Int J STD AIDS. 2023;34(6):366‐373.
Rao AK. Interim clinical treatment considerations for severe manifestations of Mpox—United States, February 2023. MMWR Morb Mortal Wkly Rep. 2023;72:72‐243.
Altmann S, Brandt CR, Murphy CJ, et al. Evaluation of therapeutic interventions for vaccinia virus keratitis. J Infect Dis. 2011;203(5):683‐690.
Hu G, Wang MJ, Miller MJ, et al. Ocular vaccinia following exposure to a smallpox vaccinee. Am J Ophthalmol. 2004;137(3):554‐556.
Fillmore GL, Ward TP, Bower KS, et al. Ocular complications in the Department of Defense Smallpox Vaccination Program. Ophthalmology. 2004;111(11):2086‐2093.
Cinatl J, Bechtel M, Reus P, et al. Trifluridine for treatment of mpox infection in drug combinations in ophthalmic cell models. J Med Virol. 2024;96(1):e29354.